A Phase IV Prospective, Double-blind, Double-dummy, Randomised, Crossover Study to Assess the Impact on Daily Cognitive Functioning of Quetiapine Fumarate Immediate Release (Seroquel IR) Dosed Twice Daily and Quetiapine Fumarate Extended Release (Seroquel XR) Dosed Once Daily in the Evening in Patients With Stable Schizophrenia.

Trial Profile

A Phase IV Prospective, Double-blind, Double-dummy, Randomised, Crossover Study to Assess the Impact on Daily Cognitive Functioning of Quetiapine Fumarate Immediate Release (Seroquel IR) Dosed Twice Daily and Quetiapine Fumarate Extended Release (Seroquel XR) Dosed Once Daily in the Evening in Patients With Stable Schizophrenia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2015

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms eXtRa
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 Oct 2012 Planned number of patients changed from 90 to 100 as reported by EudraCT.
    • 17 Oct 2012 Patient-reported outcomes presented at the 25th Annual Congress of the European College of Neuropsychopharmacology.
    • 26 Jul 2012 Primary endpoint added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top